# A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

> **NCT00740051** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 227 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Linagliptin Placebo
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT00740051
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740051, "A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00740051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*